

Patient:
DOB: Age: Gender: F
Patient Identifiers:
Visit Number (FIN):


Client:

Physician:

ARUP Test Code: 2012521

Collection Date: 05/10/2019
Received in lab: 05/11/2019
Completion Date: 05/13/2019

FibroMeter (fibrosis score) **Patient Score (Range 0-1)** **Metavir Classification¹**
0.94 **F3/F4**
Equal probability between F3 and F4



Patient Blood Marker Results

Marker	Result	Reference Interval	Units
ALT	19	5-40	U/L
AST	22	9-40	U/L
Ferritin	209	18-340	ng/mL
Glucose	219	<=100	mg/dL
Platelets ²	155		k/uL
Weight ²	155		lbs

Interpretive Information

- Calculations for the final report are based on accurate data for age, weight (\pm 5 pounds) and platelet count. If any of the information needs to be corrected, please contact ARUP Client Services at (800) 242-2787.
- The Echosens FibroMeter NAFLD profile serves as a surrogate marker of liver fibrosis in patients with non-alcoholic fatty liver disease. Results may be inaccurate in patients who were not fasting at blood draw, or with other etiologies or chronic liver diseases, such as viral hepatitis or alcoholic liver disease. A proprietary algorithm calculates results from 5 blood markers along with age and weight to provide a patient score (0-1) and a correlated fibrosis stage (Metavir F0-F4). Patients must be fasting at the time of blood draw. Results should be interpreted in conjunction with the patient's clinical history.
- Results should be interpreted with caution if the patient is: under 18 years of age; pregnant; has acute hepatitis; other cause of chronic liver disease; severe chronic inflammatory disease other than liver disease, such as arthritis, organ failure other than liver, such as kidney; iron deficiency; unstable glucose levels; unstable weight.

¹ Metavir is a histological scoring system for determining the extent of liver fibrosis and inflammation.

STAGE OF FIBROSIS (F scale)
F0 = no fibrosis
F1 = portal fibrosis without septa
F2 = portal fibrosis with few septa
F3 = numerous septa without cirrhosis
F4 = cirrhosis

² Values provided by the client.

Test developed and characteristics determined by ARUP Laboratories. See Compliance Statement B: aruplab.com/CS



Patient:
ARUP Accession: 19-130-402173